NasdaqGM:ATAIPharmaceuticals
A Look At AtaiBeckley (ATAI) Valuation After Positive BPL-003 Data And US Psychedelic Review Support
AtaiBeckley (ATAI) has been in focus after peer reviewed Phase 2a data for its BPL-003 program showed rapid, sustained reductions in depression scores, alongside a US executive order supporting psychedelic therapy review pathways.
See our latest analysis for AtaiBeckley.
The latest share price of $4.71 comes after a 38.94% 30 day share price return and a 21.71% year to date share price return. The 1 year total shareholder return of 209.87% and 3 year total shareholder return of 151.87% point...